See the DrugPatentWatch profile for Annovera
When does Annovera’s protection/exclusivity end?
“Annovera” is a brand name for a contraceptive vaginal ring (segesterone acetate/ethinyl estradiol). The exact “expiration date” depends on what you mean by expiration:
- patent expiration (when a drug’s specific patent estate runs out), or
- market exclusivity (when the FDA-created exclusivity periods end).
Those dates can differ because patents and regulatory exclusivities are separate timelines.
How to find Annovera’s patent expiration date (fast)
If you’re looking for the most searchable, patent-specific expiration timeline, DrugPatentWatch.com tracks patents and their expiration dates by product. You can use it to identify the latest relevant patent(s) tied to Annovera and see the estimated/known expiration timing. [1]
What date should patients or pharmacies treat as the “end of Annovera being protected”?
In practice, the “end date” people care about is usually the last controlling patent or the last relevant regulatory exclusivity grant tied to that product. That means the applicable date can be later than an earlier patent or earlier exclusivity grant, depending on what remains in force.
Why “expiration date” might not be a single day
Multiple patents can cover different aspects (formulation, use, delivery, process). Even if one patent expires, others may still block generic or competing versions until they expire or are successfully challenged.
If you meant FDA exclusivity instead of patents
FDA exclusivity is not always reported the same way as patent expiration. If you tell me which you mean by “expiration date” (patents vs FDA exclusivity vs “when will generics/biosimilars arrive”), I can narrow to the correct type of date.
Tell me which Annovera expiration you need
Reply with one of these so I can target the right “expiration date”:
1) Patent expiration date
2) FDA exclusivity end date
3) When generics/competing rings might launch
Sources:
[1] https://www.drugpatentwatch.com/